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ABSTRACT Psoriasis vulgaris is a well-known systemic inflammatory disease 
accompanied by many cardiac, renal, and metabolic manifestations. In recent 
years, hematological parameters have been studied in different systemic dis-
eases as markers for inflammation. In this study, we investigated the possible 
association between the hematological parameters, namely neutrophil-to-lym-
phocyte ratio (NLR), platelet-lymphocyte ratio (PLR), red cell distribution width 
(RDW), and Psoriasis Area Severity Index (PASI) scores, in patients under treat-
ment for psoriasis.
Forty-five patients with moderate to severe psoriasis and PASI values of 7 or 
greater were included in the study. Patients with other inflammatory diseases 
were excluded. All the patients were treated according to the severity of the 
disease. Hematological parameters and PASI were examined at baseline and at 
month 3, 6, 9, and 12. 
Twenty-seven patients (60%) were women, and the mean age was 42.2 years. 
No statistically significant association was found between PASI values and NLR, 
PLR, or RDW at months 0 and 12. The mean platelet volumes increased only at 
month 3, and lymphocyte counts increased significantly at all months. However, 
platelet counts decreased significantly only at month 6, 9, and 12, while RDW 
decreased significantly only at month 3. All the remaining parameters such as: 
neutrophils count, lymphocyte count, and erythrocyte sedimentation rate de-
creased significantly.
The decrease in RDW and the increase in the mean platelet volume accompa-
nied by a decrease in PASI values may represent contributing prognostic he-
matologic parameters to predict clinical progress and treatment response of 
patients with moderate-severe psoriasis during the first 3 months of treatment.
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INTRODUCTION
Psoriasis vulgaris is a systemic multifactorial dis-
ease caused by both genetic factors and environmen-
tal interactions (1). Hematological parameters such as 
neutrophil-to-lymphocyte ratio (NLR), platelet-lym-
phocyte ratio (PLR), and red cell distribution width 
(RDW) have been widely investigated as new inflam-
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mation markers for systemic inflammatory internal 
diseases (1-5). Since chronic dermatological diseases 
including psoriasis vulgaris are known to involve an 
inflammatory process, it is necessary to examine the 
possible role of these parameters and their statisti-
cal correlations in patients with different severities of 
psoriasis. Furthermore, evaluating the role of these 
markers in determining severity is also important.
The Psoriasis Area and Severity Index (PASI) scores 
of patients decrease over the course of treatment. We 
investigated whether NLR, PLR, RDW, or cell counts 
can be used as a prognostic factor for patients with 
moderate-to-severe psoriasis. The correlation be-
tween these parameters and the severity of psoriasis 
was also evaluated.
PATIENTS AND METHODS
This prospective, single-blinded study included 45 
patients with moderate-to-severe psoriasis vulgaris 
that were referred to the Dermatology Department of 
Istanbul Medipol University in Istanbul, Turkey from 
March 2016 to January 2017. The study was approved 
by the local ethics committee of the same university 
(Approval number: 66291034-604.01.01-E2043). All 
the patients were diagnosed by clinical and histo-
pathological examination. Written informed consent 
was obtained prior to the study. Sixty percent of the 
patients (27) were women. Eligibility requirements 
were being 16 years or older, having a clinical diagno-
sis of psoriasis for at least 6 months, having any form 
of moderate-to-severe psoriasis defined as 10% or 
more of body surface area affected, a PASI score of 7 
or greater, and a Physician’s Global Assessment of at 
least moderate severity at the baseline visit. The pa-
tients with PASI of 7-12 were considered to have mod-
erate psoriasis vulgaris, while those with PASI greater 
than 12 were classified as having severe psoriasis 
vulgaris. Pregnant or lactating women, smokers, and 
patients with immunocompromised diseases, ane-
mia, vitamin B12 or folate deficiencies, any infection 
or any other inflammatory disease including diabetes 
mellitus, peripheral arterial disease, Crohn’s disease, 
ulcerative colitis, Behçet’s disease, vasculitis, myocar-
ditis, coronary arterial disease, hyperlipidemia, hyper-
tension, pulmonary embolism, malignancy, hepatic 
or renal diseases, and malnutrition were excluded. 
Other exclusion criteria were being under treatment 
of anti-psoriatic, anti-inflammatory, or anti-coagulant 
medication such as topical steroids, calcipotriol, sys-
temic corticosteroids, colchicum-Dispert, cyclospo-
rine, acitretin, methotrexate, or oral contraceptive 
pills for the last 6 months, undergoing phototherapy, 
or having bleeding diathesis. All the patients were 
treated according to the current intensity of their 
disease using topical or systemic drugs such as cyclo-
sporine, acitretin, methotrexate, or phototherapy. Of 
the all patients, 10 had used acitretin, 4 had used cy-
closporine, 3 had used methotrexate, and 3 patients 
had undergone narrow-band UV-B treatment before 
the study. Additionally, 20 of the patients had already 
been treated with topical agents, either calcipotriol 
or corticosteroids. The PASI scores were recorded be-
fore treatment and at month 0, 3, 6, 9, and 12. Rou-
tine hematological parameters, namely white blood 
cell (WBC) count, neutrophil count (NC), lymphocyte 
count (LC), platelet count (PC), mean platelet volume 
(MPV), and erythrocyte sedimentation rate (ESR), 
were investigated at each visit. Non-selective inflam-
matory markers, NLR, PLR, and RDW, were examined 
before treatment and at month 0, 3, 6, 9, and 12. The 
statistical correlation between these inflammation 
markers and PASI was examined at months 0 and 12. 
Paired comparisons were performed between base-
line values and those measured at each visit. None of 
the patients withdrew from the study.
2 mL of venous blood samples was taken into 
tubes containing ethylenediaminetetraacetic acid 
(EDTA). At month 0, 3, 6, 9, and 12, all the blood ma-
terials were analyzed using a hemogram analysis ma-
chines for an hour (Sysmex xt-2000i osaka, Japan) to 
record NLR (%), PLR (%), RDW (%), WBC (10E3/uL), NC 
(10E3/uL), LC (10E3/uL), PC (10E3/uL), MPV (fL), and 
ESR (mm/hr). The normal ranges were 4.4-11.3 10E3/
uL for WBC, 1.8-7.7 10E3/uL for NC, 154-386 10E3/uL 
for PC, 7.8-11 fL for MPV, 0.375-7.7% for NLR, 32.08-
386% for PLR, 11.5-15% for RDW, and 0-15 mm/hr 
(men) and 0-20 mm/hr (women) for ESR. 
Statistical analysis
The Number Cruncher Statistical System 2007 
(Kaysville, Utah, USA) was used for the statistical 
analysis. For evaluation of the data, in addition to de-
scriptive statistical methods (mean, standard devia-
tion, median, frequency, ratio, minimum, maximum), 
a Friedman test was performed to analyze 3 or more 
follow-up datasets of the parameters showing an ab-
normal distribution, and a Wilcoxon signed-ranks test 
was used for dichotomous comparisons. P<0.05 was 
accepted as statistically significant.
RESULTS
Twenty-seven patients (60%) were women. The 
patients’ age-range was 25-67 (mean ± Standard De-
viation: 42.2±13.3). The baseline PASI values ranged 
from 10.4 to 46 (mean: 23.40±10.00). The results of 
the blood sample analysis at month 0 were as follows: 
WBC count 5.2-11.6 10E3/uL (mean: 8.3), NC 2.65-6.25 
10E3/uL (mean: 5), LC 1.57-3.9 10E3/uL (mean: 2.2), 
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ESR 1-50 mm/hr (mean: 12 mm/hr), MPV 6.21-11.4 
fL (mean: 9.2), NLR 1.22-2.95% (mean: 2.1%), PLR 
59.1-160.5% (mean: 99.5%), RDW 11.6-17.3% (mean: 
13.8%) (Table 1, Table 2). Hemoglobin levels, vitamin 
B12, and folate were within the normal range in all 
patients.
Paired comparisons showed a statistically sig-
nificant decrease in the PASI values (P<0.01) at each 
visit compared with the baseline values (P=0.001). 
However, the assessment of the correlation between 
the PASI values and NLR, PLR, and RDW at months 0 
and 12 showed no significant statistical association 
(P>0.05) (Table 3). 
The changes in WBC at month 3, 6, 9, and 12 
compared with the baseline values at month 0 were 
not significant (P>0.05) (Table 2). MPV significantly 
increased only at month 3 (p=0.033; P<0.05). LC sig-
nificantly increased (P<0.01) at month 3, 6, 9, and 
12 (P=0.001, P=0.001, P=0.003, and P=0.001, respec-
tively). PC was noted to have significantly decreased 
at month 6, 9, and 12 (P<0.05) (Table 2). RDW signifi-
cantly decreased only at month 3 (P=0.007; P<0.01) 
(Figure 1). All the remaining parameters (NC, PLR, and 
NLR) significantly decreased at each visit compared 
with month 0 (P<0.01) (Figure 2 and Figure 3). Fur-
thermore, the changes in the ESR values measured at 
month 0, 3, 6, 9, and 12 were statistically significant 
(P=0.001; P<0.01). The results of paired comparisons 
showed a statistically significant decrease in the ESR 
values (P<0.05) at all visits (P=0.001, P=0.029, P=0.001, 
and P=0.005 for months 3, 6, 9, and 12, respectively). 
DISCUSSION
Psoriasis vulgaris is a chronic systemic inflamma-
tory disease accompanied by abnormal proliferation 
of keratinocytes and circulating inflammatory cyto-
kines (1-6). The role of inflammatory cytokines in pso-
riasis vulgaris, e.g. C reactive protein (CRP), e-selectin, 
intra-cellular adhesion molecule-1, haptoglobin, in-
terleukin (IL) 1-β, IL-6, IL-8, IL-12, and IL-18, and tumor 








Month 3 6.85-11.8 (9.7) 9.41±1.67
Month 6 6.13-11.8 (10.0) 9.54±1.64
Month 9 6.02-11.8 (9.4) 9.25±1.69
Month 12 6.13-11.9 (9.7) 9.16±1.66




Month 3 51.1-132.9 (78.5) 87.88±25.34
Month 6 43.9-140.5 (87.7) 85.59±26.73
Month 9 43.5-134.4 (83.3) 82.28±22.57
Month 12 43.5-110.9 (82.2) 82.21±21.87




Month 3 11.57-16.3 (12.9) 13.56±1.59
Month 6 11.7-16.9 (13.5) 14.15±1.70
Month 9 12.2-19.6 (14) 14.49±1.94
Month 12 10.5-17.2 (13.9) 14.15±2.04




Month 3 2-40 (6) 9.80±9.99
Month 6 2-33 (6) 9.93±9.77
Month 9 2-33 (6) 8.33±8.53
Month 12 2-33 (6) 9.33±9.04




Month 3 1.2-18 (5.4) 5.52±4.36
Month 6 0-15.6 (2.0) 3.57±4.29
Month 9 0-14.8 (1.2) 2.17±3.58
Month 12 0-17.6 (1.2) 2.64±4.51
aFriedman Test; bWilcoxon Signed Ranks Test; *P<0.05; **P<0.01; MVP: mean platelet volume; PLR: platelet-lymphocyte ratio; 
RDW: red cell distribution width; ESR: erythrocyte sedimentation rate; PASI: Psoriasis Area Severity Index
Table 1. The evaluation of the hematological parameters at month 0, 3, 6, 9, and 12
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necrosis factor (TNF)-α has been demonstrated (6). 
Recently, it has been suggested that psoriasis is not 
just a skin condition but a multi-system disease affect-
ing the bone and articular system, kidneys, myocar-
dium, and peripheral blood (1). Thus, there is still an 
ongoing search for a biomarker for psoriasis vulgaris. 
Inflammatory markers such as highly sensitive-CRP, 
RDW, NLR, and PLR have been shown to increase in 
many chronic inflammatory diseases, indicating the 
presence and severity of disease activities (1-5). How-
ever, to date only one retrospective study has been 
undertaken to assess the possible role of RDW as a 
biomarker for the severity of psoriasis vulgaris (7,8).
RDW is a measure of variability in the size of 
circulating erythrocytes (anisocytosis) (9). It is cal-
culated by dividing the standard deviation of red 
blood cell (RBC) volume by the mean corpuscular 
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Figure 1. The distribution of the red cell distribution width 
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Figure 2. The distribution of the platelet-lymphocyte ratio 
(PLR) values throughout the study.
Table 2. The evaluation of the hematological parameters at month 0, 3, 6, 9, and 12
Min-Max (Median) Mean±Sd ap bp




Month 3 1.51-6.79 (4.5) 4.60±1.41
Month 6 2.38-6.45 (4.5) 4.56±1.20
Month 9 1.93-7.9 (4.8) 4.66±1.39
Month 12 1.74-6.55 (4.1) 4.28±1.29




Month 3 1.64-4.93 (2.6) 2.84±0.88
Month 6 1.43-5.36 (2.6) 2.84±0.93
Month 9 1.54-5.81 (2.6) 2.94±1.02
Month 12 1.8-5.81 (2.8) 2.92±0.93




Month 3 0.66-2.86 (1.6) 1.68±0.63
Month 6 0.65-3.04 (1.7) 1.72±0.58
Month 9 0.65-3.1 (1.7) 1.72±0.66
Month 12 0.74-2.27 (1.6) 1.51±0.42




Month 3 150-314 (232) 234.33±42.69
Month 6 150-298 (233) 225.00±46.64
Month 9 148-293 (251) 230.73±48.66
Month 12 139-298 (220) 227.07±46.88




Month 3 4.04-12.41 (8.2) 8.601±2.14
Month 6 5.82-13.23 (8.3) 8.50±2.01
Month 9 5.13-12.6 (8.4) 8.69±2.10
Month 12 4.55-12.28 (8.1) 8.25±2.15
aFriedman Test; bWilcoxon Signed Ranks Test; *P<0.05; **P<0.01; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-lym-
phocyte ratio; WCB: white blood cell count
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tiate causes of anemia. RDW is known to increase in 
several conditions including pregnancy, inflamma-
tory diseases e.g. thrombocytopenic purpura, inflam-
matory bowel diseases, anemia, blood hemolysis, 
blood transfusion, and ineffective red cell production 
in cases of iron, vitamin B12, or folate deficiencies 
(5,10). Elevated RDW values have been reported in 
myocardial infarctions, stroke, cardiac failure, pulmo-
nary hypertension, and peripheral arterial diseases 
(2,4,5) as well as Alzheimer’s, diabetes mellitus, and 
rheumatoid arthritis (11-13). A higher RDW is consid-
ered a strong and independent negative predictive 
mortality marker indicating an adverse outcome. De-
creased kidney function has been implicated for the 
negative effect of RDW. Furthermore, increased RDW 
often accompanies elevated levels of highly sensitive 
CRP and neurohumoral markers (β-type natriuretic 
peptide) and lower levels of anti-oxidative elements 
e.g. selenium (14). In inflammatory diseases, circu-
lating cytokines are responsible for the lower anti-
oxidant status, which shows the damaging oxidative 
effects predominant on all body systems including 
the hematological system. Thus, immature erythro-
poiesis causes low cell survival and juvenile circulat-
ing erythrocytes, resulting in higher RDW. Increased 
inflammation means greater oxidative stress and a 
further increase in RDW (15). Based on this evidence, 
we believe that RDW is not only a routine diagnostic 
parameter but may also act as a prognostic marker 
in moderate-to-severe psoriasis in the first three 
months of treatment. However, it is not certain why 
RDW showed a positive correlation with PASI scores 
only during the early treatment period (month 3) and 
not in the later phases. The release of cytokines after 
the initiation of treatment may have caused an onset 
of an anti-inflammatory, anti-oxidant effect, trigger-
ing a regular hematopoiesis and mature erythrocytes 
(low RDW) that may have diminished over time. On 
the other hand, Coimbra et al. found that enhanced 
RBC damage, aging and clearance caused erythroid 
disturbance in Portuguese patients with psoriasis 
(16). The authors also reported that RBC was lower 
in patients with psoriasis and several changes indi-
cating an enhanced damage and/or ageing process 
were present, which seemed to be strongly con-
nected with neutrophil activation, oxidative stress, 
and disease deterioration (16). Since erythroid distur-
bance was not completely resolved after a successful 
treatment, it has been suggested that RDW does not 
correlate with PASI.
In a retrospective study investigating the asso-
ciation of RDW with psoriasis severity, RDW was re-
ported to have a significant correlation with ESR, but 
not CRP (7). However, ESR was significantly correlated 
with CRP. In contrast, Yeşil et al.reported a significant 
correlation of RDW with both ESR and CRP in patients 
with inflammatory bowel disease (17). In another 
clinical study investigating inflammatory biomark-
ers in patients with rheumatoid arthritis, RDW was 
found to be significantly correlated with only CRP 
(13). Moreover, RDW was not correlated with PASI 
(7). RDW was reported to be significantly increased 
in patients with a PASI of greater than 12 (severe) 
compared with patients with a PASI less than 7 (mild) 
(7). However, no significant difference was reported 
between patients with moderate and severe psoria-
sis vulgaris. Additionally, Doğan et al. reported that 
patients with psoriasis who do not have any major 
cardiovascular risk factors still have high levels of CRP 
and RDW, supporting the hypothesis that psoriatic in-
flammation itself can simultaneously cause CRP and 
RDW elevation (8). A previous case-control study car-
ried out on 50 patients with psoriasis and 50 healthy 
control subjects examined the correlation between 
platelet count, MPV, and RDW with PASI values (18). 
The mean values for MPV and RDW were found to be 
higher and the platelet count lower compared with 
controls in patients of both sexes . The MPV values in 
male patients and platelet counts in female patients 
were reported to show strong positive and negative 
Table 3. The association between Psoriasis Area 
Severity Index (PASI) and hematological param-
eters
Month 0 Month 12
r P r P
PASI & NLR 0.243 0.108 -0.048 0.752
PASI & PLR 0.189 0.213 -0.091 0.551










r: Spearman’s correlation coefficient; NLR: neutrophil-to-
lymphocyte ratio; PLR: platelet-lymphocyte ratio; RDW: red 
cell distribution width; MPV: mean platelet volume
3
Figure 3. 
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Figure 3. The distribution of the neutrophil-to-lymphocyte 
ratio (NLR) values throughout the study.
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correlation with the PASI score, respectively (18). As 
a result of this study, it was similarly concluded that 
rising MPV and decreasing PLR could be good indica-
tors of disease severity and progression that help in 
assessing the treatment course of the disease (18). 
The present study had certain limitations such as 
the lack of a control group. However, we excluded the 
presence of all probable factors that may have affect-
ed the evaluated biomarkers. For example, systemic 
methotrexate intake which triggers folate or vitamin 
B12 deficiency may also cause higher values of MCV 
and RDW in patients with psoriasis (7). Since hemo-
globin levels were within the normal range and none 
of the patients were under methotrexate treatment, 
we easily excluded the probability of iron, folate, or 
vitamin B12 deficiencies. We believe that the compar-
ison of the change in the PASI values and biomark-
ers during the treatment period compared with the 
baseline and the examination of their possible affilia-
tion improved the value of the study.
Coimbra et al. did not consider RDW to be a prog-
nostic marker to estimate the severity of psoriasis 
vulgaris, but associated higher RDW with psoriasis 
vulgaris (16). In another study that examined MPV 
and RDW in patients with pityriasis rosea, no signifi-
cant difference was reported between the patient 
and control groups (3). The lower RDW values seen 
in acute pityriasis rosea were attributed to a viral in-
fection that could have suppressed the bone marrow 
and resulted in a temporary loss in erythropoietic 
activity (3). Moreover, in systemic sclerosis, RDW was 
reported as a valuable measure of multiple patho-
logical processes including extensive vasculopathy, 
fibrosis, and ongoing inflammation (19). Based on the 
results, we conclude that RDW is only correlated with 
early PASI measurements since RBC distribution and 
erythropoiesis may not really change after long-term 
anti-psoriasis treatment.
MPV is another determinant of inflammation eas-
ily measurable using an automated hematology ana-
lyzer in a routine complete blood cell analysis (20). 
As a sign of platelet function and activation, MPV is 
elevated during the increased peripheral destruction 
of platelets and reduced during impaired platelet 
production (20). MPV has been studied as an inflam-
matory marker of cutaneous vasculitis, psoriasis, and 
cardiovascular and rheumatologic diseases. Further-
more, Topal et al. reported that the MPV value was 
higher in preschool children with atopic eczema, 
whereas RDW was not statistically different (21). In 
recent studies, elevated MPV levels have been ob-
served in diseases such as psoriasis, psoriatic arthritis, 
Behçet’s, diabetes mellitus, acute coronary syndrome, 
stroke, preeclampsia, renal artery stenosis, and hyper-
cholesterolemia (20,22-25). In a study that examined 
the effects of colchicine in patients with recurrent 
aphthous stomatitis, NLR, WBC, and RDW significant-
ly decreased; however, no changes were seen in MPV, 
PLR, and hemoglobin levels in patients under colchi-
cine treatment (26). In the current study, similar to the 
RDW results, the MPV values significantly increased 
only at month 3, indicating a significant change only 
in the early treatment period. This may be attributed 
to the acute temporary destructive or suppressive ef-
fects of a systemic anti-psoriatic drug. Furthermore, 
following the rise in MPV at month 3, PC significantly 
decreased at month 6, 9, and 12 due to the destruc-
tion of platelets.
CONCLUSION
RDW measurement is a simple, efficient, and cost-
effective tool to include in routine whole-blood exam-
inations to monitor patients with psoriasis vulgaris in 
everyday practice. It can be concluded that RDW may 
help predict the severity of psoriasis vulgaris faster 
than the measurement of PASI values during the early 
treatment period. Further multi-centered, controlled 
clinical studies are needed to confirm the prognos-
tic importance of biomarkers such as RDW or MPV in 
patients with psoriasis vulgaris. Furthermore, cyto-
genetic and bone marrow evaluations would clearly 
reveal the exact mechanism of erythroid disturbance 
in these patients. Finally, the effect of specific drugs, 
e.g. colchicine, could be examined.
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